The United States licenses the third Covid-19 vaccine

Millions of Americans will be vaccinated with Covid-19 single-dose vaccine from Johnson & Johnson pharmaceutical company in the next few weeks.

The J&J vaccine is the third Covid-19 resistant vaccine to be licensed in the United States. Photo: Shutterstock

The US licensing of Johnson & Johnson single-dose Covid-19 vaccine (J&J vaccine) will pave the way for the vaccine to win the approval of many other countries. The J&J vaccine is the third Covid-19 resistant vaccine to be licensed in the US, after the two-dose vaccine from the Pfizer-BioNTech alliance and the Moderna pharmaceutical company.

The US Food and Drug Administration announced on February 27 that it had licensed the emergency use of J&J vaccines for people aged 18 and over after reaching a consensus from an outside expert panel on 26. /2. The vaccine batches will be delivered to the vaccination site from February 28 or March 1.

President Joe Biden appreciated this ratification move, but the White House “boss” warned Americans not to get excited too soon. “Things are still likely to get worse again as new strains spread,” the US President recommended. Mr. Biden also called on people to continue washing hands, wearing masks and maintaining social distance.

“There is light at the end of the tunnel, but we cannot let our guard down now or take it for granted,” Mr. Biden said.

According to results recorded from important tests, vPfizer and Moderna, a two-dose accine, was developed based on RNA genetic material, giving a higher antiviral effect than the one-dose J&J vaccine. However, it is difficult to compare the efficacy directly between these vaccines because the trials have different objectives, while the J&J vaccine is being tested on current and potentially new strains. spread higher.

“We think people should use vaccines that they can access,” says Dr. Janet Woodcock, acting senior commissioner of the US Food and Drug Administration, advises, agrees that all three Covid-19 resistant vaccines licensed in the US have not been directly comparable.

“We found that all three of these vaccines are effective, helping to prevent hospitalizations and deaths, so they need to be used,” said Janet Woodcock.

In a global trial of 44,000 people, the J&J vaccine was assessed to be 66% effective against moderate to severe Covid-19 resistance 4 weeks after injection. The J&J vaccine is 100% effective in preventing hospitalizations and deaths caused by Covid-19.

The J&J vaccine trial report reports very few serious side effects following the use of the vaccine. This has strengthened preliminary evidence that this vaccine reduces the number of asymptomatic infections.

However, the US Food and Drug Administration on Feb. 27 rejected the notion that the J&J vaccine helps prevent the spread of Covid-19 in humans, and said there is currently no data to determine the possibility. How long does the vaccine resistance last?

The J&J vaccine is expected to be widely used globally as it is a vaccine that can be transported and stored at normal refrigerator temperatures, making it much easier to distribute than the two required vaccines. frozen in transit of the Pfizer – BioNTech alliance and Moderna pharmaceutical company.